Public Health Vaccines Commences First Clinical Trial Of Marburg Virus Vaccine

Public Health Vaccines, LLC (PHV), a biotechnology firm based in Cambridge, Massachusetts, has initiated a Phase 1 clinical trial to assess the safety and immunogenicity of its innovative single-dose vaccine, PHV01, targeting the Marburg virus. This virus is known for causing Marburg virus disease, a rare but severe hemorrhagic fever with a fatality rate of up to 88%. The World Health Organization has listed it as a priority pathogen due to its potential to spark future outbreaks and pandemics. The U.S. trial is a significant step in combating this naturally occurring public health threat.

The trial, identified as NCT06265012, is designed as a randomized, single-blind, placebo-controlled, ascending-dose study involving healthy adults. It aims to evaluate the vaccine's safety and its ability to provoke an immune response. PHV01 utilizes the recombinant vesicular stomatitis virus (rVSV) vector platform, a system previously developed by the Public Health Agency of Canada (PHAC) and known for its rapid onset of protection after just one dose.

Funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, PHV01 has received support under contract number HHSO100201900022C. With BARDA's backing, PHV could receive up to $72 million in funding if development efforts proceed successfully. This support would facilitate the completion of a Phase 2 clinical trial and further regulatory activities leading to approval.

Joan Fusco, PHV’s Chief Operating Officer, emphasized the importance of developing vaccine countermeasures in light of recent Marburg outbreaks in Africa and other regions. She highlighted the critical nature of having clinical data ready to tackle this rising infectious disease threat. Fusco expressed gratitude towards BARDA for their continued support and acknowledged the dedication of PHV's team and collaborators in reaching this pivotal milestone.

Public Health Vaccines, LLC is dedicated to creating vaccines against emerging infectious diseases, including Marburg virus, Sudan ebolavirus, and Nipah virus. For more information about their work and developments in vaccine research, interested parties can visit www.phvaccines.com or contact them via email at [email protected].